Germany
Japan
United Kingdom
China
Dystonin (DST) human monoclonal antibody, clone H5E.Hy.4B
| Applications | IF, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Antibodies
View as table DownloadDystonin (DST) human monoclonal antibody, clone H10D-Hy-8B
| Applications | IF, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-c-myc epitope tag (Clone 9E10)
| Applications | IF, IHC, IP, WB |
| Conjugation | Unconjugated |
Recombinant Anti-c-myc epitope tag (Clone 9E10)
| Applications | IF, IHC, IP, WB |
| Conjugation | His Tag |
Recombinant Anti-c-myc epitope tag (Clone 9E10)
| Applications | IF, IHC, IP, WB |
| Conjugation | Unconjugated |
Recombinant Anti-c-myc epitope tag (Clone 9E10)
| Applications | IF, IHC, IP, WB |
| Conjugation | Unconjugated |
Recombinant Anti-c-myc epitope tag (Clone 9E10)
| Applications | IF, IHC, IP, WB |
| Conjugation | Unconjugated |
Recombinant Anti-erbB-2 (Her-2/neu) (Clone 4D5-8 (trastuzumab))
| Applications | ELISA, FC, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-V5 epitope tag (Clone SV5-P-K)
| Applications | ELISA, IF, IHC, IP, WB |
| Conjugation | Unconjugated |
Recombinant Anti-V5 epitope tag (Clone SV5-P-K)
| Applications | ELISA, IF, IHC, IP, WB |
| Conjugation | His Tag |
Recombinant Anti-V5 epitope tag (Clone SV5-P-K)
| Applications | ELISA, IF, IHC, IP, WB |
| Conjugation | Unconjugated |
Recombinant Anti-V5 epitope tag (Clone SV5-P-K)
| Applications | ELISA, IF, IHC, IP, WB |
| Conjugation | Unconjugated |
Recombinant Anti-V5 epitope tag (Clone SV5-P-K)
| Applications | ELISA, IF, IHC, IP, WB |
| Conjugation | Unconjugated |
Recombinant Anti-TRP-1, gp75 (Clone TA99)
| Applications | ELISA, FC, IF, IHC, IP, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. |
USD 523.00
2 Weeks
Recombinant Anti-IL-2R alpha (CD25) (Clone Basiliximab)
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. |
USD 523.00
2 Weeks
Recombinant Anti-alpha 5 beta 1 Integrin (Clone M200 (Volociximab))
| Applications | ELISA, FC, IF, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-CD4 (Clone CE9.1 (Clenoliximab))
| Applications | ELISA, FC, IHC |
| Reactivities | Chimpanzee, Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-ED-B domain of fibronectin (Clone A2)
| Applications | ELISA, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-ED-B domain of fibronectin (Clone G4)
| Applications | ELISA, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-TNF alpha (Clone D2E7 (Adalimumab))
| Applications | ELISA, IF, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-EGFR domain III (Clone h-R3 (Nimotuzumab))
| Applications | FC, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-CD80 (Clone IDEC-114 (Galiximab))
| Applications | ELISA, FC, IHC, IP, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-GM2 ganglioside (Clone L55-81)
| Applications | ELISA, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-CD40 (Clone 5D12)
| Applications | ELISA, FC, IHC, IP |
| Reactivities | Human, Monkey, Cynomolgus |
| Conjugation | Unconjugated |
Active filters
Applications
- IHC
Antibody Hosts
- Human
Filter by
Target Symbol
Reactivities
Isotypes
Clonalities
Conjugates
Modifications
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (5)
- This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (1)